San Mateo, United States
EpiBiologics, founded in 2022 and headquartered in the SF Bay Area, is at the forefront of protein degradation technology. The company is pioneering advancements in bispecific antibodies that specifically degrade membrane and soluble proteins, including GPCRs, leveraging its proprietary EpiTAC platform. This innovation aims to enhance therapeutic efficacy through tissue-selective degrader receptors, showing promise particularly in oncology and immunology.
Underpinned by research from Dr. Jim Wells at UCSF, EpiBiologics has gained significant traction in the biotech sector. The firm's potential to translate groundbreaking science into clinical applications has attracted robust financial backing. Recently, the company secured a $107.00M Series B investment on January 1, 2026, with contributions from prestigious investors including GV, Johnson & Johnson Innovation, Novartis Venture Fund, and others.
By continually advancing its pipeline, EpiBiologics is well-positioned to make significant strides in transformative therapies, enhancing its appeal as a prime candidate for further investment.
